Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab

Abstract

Objectives: The pro-inflammatory proteins calprotectin (a heterocomplex of S100A8/A9) and S100A12 have been associated with disease activity in rheumatoid arthritis (RA). The aim of this study was to compare their potential as biomarkers in a prospective study of RA patients starting with infliximab as their first biological disease-modifying anti-rheumatic drug (DMARD).

Method: Thirty-nine RA patients were examined and serum samples collected when starting with infliximab and after 3, 6, and 12 months. Calprotectin and S100A12 were analysed by enzyme-linked immunosorbent assays (ELISAs) and, together with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), measured at all time points. A disease activity score of 28 joints (DAS28) was calculated. Radiographs of the hands, wrists, and feet were taken at baseline and after 3 years, and assessed according to the modified Sharp/van der Heijde (SvH) score. Responsiveness was evaluated according to the European League of Associations for Rheumatology (EULAR) response criteria based on 28 joints.

Results: Both S100 proteins were significantly higher in seropositive than in seronegative patients (p = 0.01). Calprotectin correlated significantly with CRP (ρ = 0.51–0.75), ESR (ρ = 0.32–0.52), and DAS28 (ρ = 0.32–0.62). S100A12 correlated with calprotectin (ρ = 0.62–0.77) and CRP (ρ = 0.32–0.63). The S100 proteins, and especially calprotectin (ρ = 0.23–0.39), showed weak associations with radiographic progression, unlike CRP/ESR. None of the S100 proteins could predict responsiveness.

Conclusions: Calprotectin showed the strongest correlation with measures of disease activity and may be better than S100A12 when evaluating disease activity in RA patients. More extensive studies are needed to further compare the predictive value of the S100 proteins relative to radiographic progression.

Acknowledgements

We thank MK Fagerhol for his development of the S100A12 ELISA and generous supply of reagents. We also thank AG Kvalvik and physicians at the Departments of Rheumatology at Haugesund Rheumatism Hospital, Førde Hospital, and Haukeland University Hospital for clinical evaluations of the patients. We are grateful to the patients who were willing to participate in this study. This work was partially supported by an unrestricted grant from Schering-Plough.